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Safety Management
UMS Safety Managem ent (SM), in partnership w ith the UMaine Office of Research Compliance, works w ith researchers to enco urage an d
Sl1pport the safety of employees throughout the state and beyond. Safety Managem ent supports the research comm lmity in a multit ude
of ways including; working with UMaine and UMS Human Resources, UMS Risk Management, an d the UMaine researcher's chain of
command.
Some more detailed examples include: examining job descriptions with Human Resources (HR), assisting supervisors with the evaluation of
the health and safety checklists, co nducting site visits for Pr incipal Investigators, perform ing client observations for the Office of Research
Compliance, r eviewing Fieldwork Hazard Assessm ents and Safety Plans, answer ing specialized or unique occupational safety train ing
questions for personnel, and monitoring chemical purchases behind t he scenes. SM supports the UMaine chain of command by
r emaining active on organized committees (e.g., UMaine Radiation Safety Committee, Institut ional BiosafetY. Committee, and Institutional
Animal Car e and Use Committee) which help link the compliance structure between the cam pus and the system.
In addition to the aforementioned activities, SM also receives Proposal Approval Routing System (PARS) notifications surrounding
specialized or unique concerns that UMaine research has chosen to address directly. Some examples are:
• The use of radioactive isotopes (e.g. benchtop or field work), equipment containing ra dioactive materials (sealed sources), or ionizing
radiation-producing equipment (e.g. electron microscopes, x-ray equipment)
• The use of Class 3b or 4 lasers
• Activities which require m edical evaluations for potent ial exposure to Particu larly Hazardous Substances defined in the UMS chem ical
hygiene 12lan tem P-late, specific OSHA r egulated substances (e.g. lead, asbestos), and pesticides (e.g. acute toxicity single exposure
category 1. and 2)
• Any project activities involve human underwa ter activities (scuba diving, hookah diving, or breath-h old/free diving)
• Activities w here resp iratory protection (Self Contained Breathing Apparatus, elastomer ic or filter ing face piece respirators) are
necessary clue to health exposures or lack of engineer ing controls (chemical fum e hoods) in place
• Activities which have excessive noise in excess of 85db (e.g. having to shout or raise you r voice w hen w ithin 6' of another person)
• Activities w hich require interaction with human blood, tuberculosis, wild animals, possible exposure to zoonotic diseases and
infectious material
• Activities which require special SM train ing r e~uirements
• Activities which generate hazardous waste paid fo r through indir ect cost recovery

SM may reach out by way of automatic emails through PARS or directly from Safety Management. The guidance and suggestions provided
in those communications are only as good as the infor mation you provide as an input to PARS. If you are working with the concerns above,
and have had no co ntact w ith SM post 3 weeks from submitting your r esearch proposal, contact safety management at sem@maine.edu.

It is especially important to verify that the SM recommendations have been completed prior to grant award to prevent
interruptions or postponements to your research. If you ar e work ing with the noted concerns above, and not involved with PARS, yo u
should also be proactively comm unicating with your chain of comman d and UMS Safety Management.
For more information (such as Policies/Gui dance/Programs, tra ining infor mation, and SM Staff) please visit the Safety'. Management
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Biosafety

Institutional Biosafety Commitee (IBC)
!BC Overview
Institutional Biosafety Committee (IBC} registration is r equired prior to use of 'biohazards'
Policy

Training

in research. Under UMaine policy, 'biohazard' includes recombinant or synthetic nucleic
acid molecules (including plants), biological materials/biospecimens (human and animal
blood, bodily fluids, and/or tissues), infectious agents* or select agents/ toxins. (* The

Forms & Resources
IBCFAQs

University of Maine has defined "infectious agents" as all bacterial, parasitic, fungal, viral,
and prion, included within Class 2 or higher classes; See App endix B of NIH Guidelines.)
For guidance o n whether your biohazards wor k r equires IBC or other approvals, view
the IBC Protocol Submission Decision Tree.
Questions regarding the IBC may be directed to umric@maine.edu.

May 15, 2.020 Update from the NIH Office of Science Policy: The

NIH Office of Science Policy has issued Frequently Asked Questions
(FAQs) regarding interim biosafety guidance fo r research with SARSCoV-2 and relevant Institutional Biosafety Committee (IBC)
requirem ents under the NIH Guidelines. Appendix B of the NIH

Guidelines provides the basis for the class ification of biohazardous
agents by Risk Group (RG). At the present time, SARS-CoV-2 best
meets the definition of a RG3 agent an d IBCs should consider the
agent to b e RG3 as a starting point in their risk assessments w hen
reviewing research subject to the NIH Guidelines. The RG
classification may change over time as additional information about
the virus, such as potential treatments or the development of an
effective vacc ine, becomes available.

Additional interim biosafety_guidance for research with SARS-CoV-2
and IBC re~u irements under the NIH Guidelines

Up next: Policy
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umr ic@maine_edu
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